Successful anticoagulation with hirudin in a patient with mesenteric venous thrombosis and multiple coagulation abnormalities

Abstract

A case of multiple thrombotic diatheses discovered in the setting of mesenteric venous infarction is discussed. The patient had deficiencies of protein C, protein S, antithrombin III; was heterozygous for factor V Leiden; and had polycythemia vera. Adequate anticoagulation could not be established with heparin administration and hirudin was used. The diagnosis of mesenteric venous infarction, thrombotic tendency of multiple coagulation diatheses, and use of hirudin are discussed.

Keywords

deep vein thrombosis hirudin polycythemia vera protein C deficiency thrombosis

References

Wilson C , Walker ID , Davidson JF , Imrie CW. Mesenteric venous thrombosis and antithrombin III deficiency. J Clin Pathol 1987; 40: 906-908.

Hansen HJ , Christoffersen JK. Occlusive mesenteric infarction. A retrospective study of 83 cases. Acta Chir Scand 1976; 472 (Suppl): 103-108.

Kairaluoma MI , Karkola P , Huttunen R , Mokka RE , Larmi TK. Mesenteric Infarction. Am J Surg 1977; 133: 188-193.

Rhee RY , Gloviczki P , Mendonca CT et al. Mesenteric venous thrombosis: still a lethal disease in the 1990’s. J Vasc Surg 1994; 20: 688-697.

Harward TRS , Green D , Bergan JJ , Rizzo RJ , Yao JST. Mesenteric venous thrombosis. J Vasc Surg 1989; 9: 328-333.

Abdu R , Zakhour B , Dallis D. Mesenteric venous thrombosis: 1911- 1984. Surgery 1987; 101(4): 383-388.

Font VE , Hermann RE , Longworth DL. Chronic mesenteric venous thrombosis: difficult diagnosis and therapy. Cleve Clin J Med 1989; 56(8): 823-828.

Gehl HB , Bohndorf K , Klose KC , Gunther RW. Two-dimensional MR angiography in the evaluation of abdominal veins with gradient refocused sequences. J Comput Assist Tomogr 1990; 14(4): 619-624.

Grieshop RJ , Dalsing MC , Cikrit DF , Lalka SG , Sawchuk AP. Acute mesenteric venous thrombosis. Revisited in a time of diagnostic clarity. Am Surg 1991; 57(9): 573-578.

10.

Miletich JP. Thrombophilia as a multigenic disorder. Semin Thromb Hemost 1998; 24 (Suppl). 13-20.

11.

Tait RC , Walker ID , Reitsma PH et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73: 87-93.

12.

Ridker PM , Miletich JP , Hennekens CH , Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277: 1305-1307.

13.

Bucalossi A , Marotta G , Bigazzi C , Galieni P , Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996; 52: 14-20.

14.

Mustafa S , Mannhalter C , Rintelen C , Kyrle PA , Lechner K , Pabinger I. Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coag Fibrin 1998; 9: 85-89.

15.

Conlan MG , Haire WD. Low protein S in essential thrombocythemia with thrombosis. Am J Hematol 1989; 32: 88-93.

16.

Koeleman BP , Reitsma PH , Allaart CF , Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035.

17.

Price DT , Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127: 895-903.

18.

Maurer B , Wray R , Shillingford J. Frequency of venous thrombosis after myocardial infarction. Lancet 1971; ii: 1385-1387.

19.

McCarthy S , Turner J , Robertson D , Hawkey C. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet 1977; ii: 800-801.

20.

Gelmers H. Effects of low-dose subcutaneous heparin on the occur-rence of deep vein thrombosis in patients with ischemic stroke. Acta Neurol Scand 1980; 61: 313-318.

21.

Warlow C , Beattie A , Terry G , Ogston D , Kenmure A , Douglas A. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-venous thrombosis after myocardial infarction. Lancet 1973; ii: 934-936.

22.

Ewenstein BM. Antithrombotic agents and thromboembolic disease. N Engl J Med 1997; 337: 1383-1384.

23.

Visentin GP , Ford SE , Scott JP , Aster RH. Antibodies from patients with heparin-induced-thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88.

24.

Hirsh J. Heparin (comments). N Engl J Med 1991; 324(22): 1565-1574.

25.

Ludwig DJ , Hauptmann E , Rosoff L Jr , Neuzil D. Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery. J Vasc Surg 1999; 30(3): 551-554.

26.

Eriksson BI , Ekman S , Kalebo P , Zachrisson B , Bach D , Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-639.

27.

Eriksson BI , Wille-Jorgensen P , Mouret P et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-1335.

28.

Monreal M , Costa J , Salva P. Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Drugs Aging 1996; 8: 171-182.

29.

Song X , Huhle G , Wang L , Hoffman U , Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999; 100(14): 1528-1532.

30.

Abu-Hajir M , Mazzeo A. The Pharmacology of antithrombotic and antiplatelet agents. Anesthesiol Clinics N Am 1999; 17(4): 749-786.